AdvisorShares Pure US Cannabis ETF

The First U.S.-Listed ETF Available – MSOS is the first actively managed U.S.-listed ETF with dedicated cannabis exposure focusing exclusively on U.S. companies, including multi-state operators. The portfolio manager allocates across an investable universe of U.S. companies spanning a variety of cannabis-related businesses. Easy Access to U.S. Cannabis Exposure – MSOS trades on the NYSE Arca exchange, offering exposure to multiple cannabis securities in a convenient, single trade. To buy U.S. cannabis companies on your own, investors will need to seek these stocks out in smaller, foreign exchanges. Experience – MSOS’ portfolio manager has deep experience in the capital markets and well-established expertise investing in highly-regulated areas in the equity markets, including cannabis. MSOS assets are held by one of the largest U.S. custodial banks, BNY Mellon.

AdvisorShares Pure US Cannabis ETF trades as MSOS on AMEX. The company is classified in Financial Services / Asset Management and reports in USD.

The current profile places the business in Asset Management. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

AdvisorShares Pure US Cannabis ETF can be compared against peers such as Avantis U.S. Large Cap Equity ETF, JPMorgan BetaBuilders Emerging Markets Equity ETF, iShares MSCI Chile ETF, State Street SPDR S&P International Small Cap ETF, Dan Ives Wedbush AI Revolution ETF, John Hancock Investments - Multifactor Developed International ETF.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $795.03M, beta of 0.82, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

MSOS currently shows total debt of N/A and beta of 0.82. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: NPORT-P (2026-05-21 00:00:00), NPORT-P (2026-05-21 00:00:00), NPORT-P (2026-05-21 00:00:00), NPORT-P (2026-05-21 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://advisorshares.com/etfs/MSOS

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.